Form 4: Tonix Pharmaceuticals Director Receives Stock Option Grant

Director Richard H. Bagger was granted 22,700 stock options in Tonix Pharmaceuticals Holding Corp. on May 12, 2026.

Summary

• Director Richard H. Bagger received a grant of 22,700 stock options.
• The options have an exercise price of $13.28 per share.
• The grant was issued under the Issuer's 2026 Stock Incentive Plan.
• The options vest on the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $13.28 exercise price.

Future Outlook

The options vest in one year, indicating a long-term retention strategy for the director.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board members remain incentivized toward company performance.

Comparison to Industry Standards

• The use of a one-year vesting schedule is consistent with standard equity compensation practices for non-employee directors in small-cap pharmaceutical companies.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on May 12, 2027, or the 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

Tonix Pharmaceuticals, TNXP, Form 4, Insider Trading, Stock Options, Director Compensation